The invention relates to a water insoluble solid crosslinked dextrin-based matrix, wherein the crosslinking agent is sodium trimetaphosphate (STMP), its use and method of preparation.

The present invention provides an improved process for preparing microparticles containing glatiramer acetate having low levels of residual organic solvent(s), in particular dichloromethane. The microparticles are incorporated into long acting parenteral pharmaceutical compositions in depot form that are suitable for subcutaneous or intramuscular implantation or injection, and that may be used to treat multiple sclerosis.

The present invention provides an improved process for preparing microparticles containing glatiramer acetate having low levels of residual organic solvent(s), in particular dichloromethane. The microparticles are incorporated into long acting parenteral pharmaceutical compositions in depot form that are suitable for subcutaneous or intramuscular implantation or injection, and that may be used to treat multiple sclerosis.

The invention relates to stable formulations comprising an anti-CLEVER-1 antibody or antigen binding fragment(s) thereof, a buffer and a stabilizing agent. The present invention further relates to stable formulations of an anti-CLEVER-1 antibody or antigen binding fragments thereof for use in treatment of various diseases and disorders.

A 17β-estradiol/vitamin C molecular complex is obtained by compounding of 17β-estradiol and vitamin C in a molar ratio of 0.25:1, 0.5:1, 0.75:1, 1:1, 1:0.25, 1:0.5, or 1:0.75. A preparation method and use of the 17β-estradiol/vitamin C molecular complex are further provided. The 17β-estradiol/vitamin C molecular complex can be distributed to a bone tissue in a bone-targeted manner, which not only significantly improves the anti-osteoporosis activity of 17β-estradiol but also effectively prevents the side effects of endometrial hyperplasia and thrombosis caused by treatment with 17β-estradiol and conjugated estrogens.

A 17β-estradiol/vitamin C molecular complex is obtained by compounding of 17β-estradiol and vitamin C in a molar ratio of 0.25:1, 0.5:1, 0.75:1, 1:1, 1:0.25, 1:0.5, or 1:0.75. A preparation method and use of the 17β-estradiol/vitamin C molecular complex are further provided. The 17β-estradiol/vitamin C molecular complex can be distributed to a bone tissue in a bone-targeted manner, which not only significantly improves the anti-osteoporosis activity of 17β-estradiol but also effectively prevents the side effects of endometrial hyperplasia and thrombosis caused by treatment with 17β-estradiol and conjugated estrogens.

A freeze-dried powder for preparing a thermogel including: from 1% to 35% of 2-[(3-aminopropyl)amino]ethanethiol or one of its pharmaceutically acceptable salt; from 40% to 85% of one or more poloxamer; and from 0.1% to 20% of one or more carbohydrate compound.

A freeze-dried powder for preparing a thermogel including: from 1% to 35% of 2-[(3-aminopropyl)amino]ethanethiol or one of its pharmaceutically acceptable salt; from 40% to 85% of one or more poloxamer; and from 0.1% to 20% of one or more carbohydrate compound.

The present invention relates to a process for the preparation of a dispersion comprising an inhalable immunosuppressive macrocyclic active ingredient in liposomally solubilized form in an aqueous carrier liquid, the process comprising the steps of a) providing a mixture comprising —the inhalable immunosuppressive macrocyclic active ingredient; —a membrane-forming substance selected from the group of phospholipids; —a solubility-enhancing substance selected from the group of non-ionic surfactants; —optionally one or more excipients; and —the aqueous carrier liquid; b) dispersing the mixture as provided in step a) to form an intermediate aqueous dispersion comprising the inhalable immunosuppressive macrocyclic active ingredient in the aqueous carrier liquid; and c) homogenizing the intermediate aqueous dispersion as formed in step b) to form the dispersion comprising the inhalable immunosuppressive macrocyclic active ingredient in liposomally solubilized form.

The present invention relates to a process for the preparation of a dispersion comprising an inhalable immunosuppressive macrocyclic active ingredient in liposomally solubilized form in an aqueous carrier liquid, the process comprising the steps of a) providing a mixture comprising —the inhalable immunosuppressive macrocyclic active ingredient; —a membrane-forming substance selected from the group of phospholipids; —a solubility-enhancing substance selected from the group of non-ionic surfactants; —optionally one or more excipients; and —the aqueous carrier liquid; b) dispersing the mixture as provided in step a) to form an intermediate aqueous dispersion comprising the inhalable immunosuppressive macrocyclic active ingredient in the aqueous carrier liquid; and c) homogenizing the intermediate aqueous dispersion as formed in step b) to form the dispersion comprising the inhalable immunosuppressive macrocyclic active ingredient in liposomally solubilized form.